High-dose naloxone in older normal subjects: implications for Alzheimer's disease.
The behavioral and cognitive effects of naloxone HCl, in doses of 5 micrograms/kg, 0.1 mg/kg, and 2.0 mg/kg administered as an IV bolus, were assessed in a double-blind, placebo-controlled, randomized study of eight normal subjects ranging in age from 44 to 74 years (mean 63). Naloxone produced mild behavioral effects with slight cognitive impairment after the 2.0 mg/kg dose only. The threshold, dose dependency, characteristics, and magnitude of these behavioral effects were similar to what has previously been reported in young normal subjects, but markedly different from those observed in patients with dementia of the Alzheimer type (DAT) matched in age to the current study sample. These data suggest that the metabolic fate of naloxone is not substantially affected by age within the range studied. The findings of this study provide further support for a role for endogenous opiate systems in the modulation of behavior and cognition, and suggest that the unusual behavioral sensitivity of patients with DAT to naloxone cannot be accounted for by the effect of age.
D000328:Adult; D000367:Age Factors; D000368:Aged; D000544:Alzheimer Disease / Q000503:physiopathology* / Q000523:psychology; D001519:Behavior / Q000187:drug effects*; D002986:Clinical Trials as Topic; D003071:Cognition / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004723:Endorphins / Q000502:physiology; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007858:Learning / Q000187:drug effects; D008297:Male; D008568:Memory / Q000187:drug effects; D008875:Middle Aged; D009270:Naloxone / Q000008:administration & dosage* / Q000494:pharmacology; D011569:Psychiatric Status Rating Scales; D011594:Psychometrics; D011897:Random Allocation
D004723:Endorphins; D009270:Naloxone